StonvexLoading…
StonvexStonvexStonvexCore line items from DLX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $538.10M | $2.13B | $1.60B | $1.06B |
Operating Income | $71.80M | $232.40M | $184.69M | $108.86M |
Net Income | $35.80M | $82.10M | $70.13M | $36.40M |
EPS (Diluted) | $0.77 | $1.80 | $1.54 | $0.80 |
Total Assets | $2.56B | $2.86B | $2.59B | $2.54B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $27.20M | $36.90M | $25.80M | $26.00M |
Free Cash Flow OCF − CapEx | $27.30M | $175.30M | $95.97M | $52.11M |
Shares Outstanding | 45.70M | 45.00M | 44.97M | 44.88M |